2025-07-16 - Analysis Report
Okay, here's an analysis of TG Therapeutics Inc. (TGTX) based on the data you provided, presented in English with numerical summaries and analysis.

**Report on TG Therapeutics Inc. (TGTX)**

**1. Performance vs. S&P 500 (VOO)**

*   **Ticker:** TGTX
*   **Company Description:** TG Therapeutics Inc. is a biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.
*   **TGTX Cumulative Return:** 68.59%
*   **VOO Cumulative Return:** 94.99%
*   **Absolute Divergence (TGTX - VOO):** -30.8%
*   **Relative Divergence:** 15.6 (This means TGTX's performance relative to VOO is in the lower end of its historical range)

**Alpha/Beta Analysis:**

| Year       | CAGR    | MDD   | Alpha   | Beta   | Cap(B) |
| :----------- | :------ | :------ | :------ | :----- | :----- |
| 2015-2017  | -6.0%   | 56.5% | -35.0%  | -0.1  | 1.3    |
| 2016-2018  | -8.0%   | 58.6% | -26.0%  | 0.0   | 0.7    |
| 2017-2019  | 74.0%   | 58.6% | 44.0%   | 0.0   | 1.8    |
| 2018-2020  | 402.0%  | 58.6% | 382.0%  | -0.4  | 8.3    |
| 2019-2021  | 125.0%  | 63.5% | 76.0%   | -0.5  | 3.0    |
| 2020-2022  | -76.0%  | 70.4% | -78.0%  | -0.6  | 1.9    |
| 2021-2023  | -350.0% | 70.4% | -368.0% | -0.8  | 2.7    |
| 2022-2024  | 71.0%   | 73.1% | 45.0%   | -0.9  | 4.8    |
| 2023-2025  | 75.0%   | 73.1% | 29.0%   | 0.4   | 6.0    |

**Analysis:** The data shows significant variability in TGTX's performance.  The Alpha values fluctuate widely, indicating periods of both substantial outperformance and underperformance relative to the market.  Beta values are generally low, suggesting relatively low correlation with the overall market. MDD(Maximum Drawdown)은 큰 변동폭을 보여주고 있습니다.

**2. Recent Stock Price Movement**

*   **Current Price:** 37.96
*   **Previous Close:** 38.92
*   **Change:** -2.47%
*   **5-day Moving Average:** 37.91
*   **20-day Moving Average:** 36.67
*   **60-day Moving Average:** 37.11

**Analysis:**  The price is slightly below the previous close, indicating a minor downward movement. The 5-day moving average is close to the current price, while the 20-day and 60-day averages are lower, suggesting a possible short-term upward trend that might be losing momentum.

**3. Risk Indicators & Expected Return**

*   **Market Risk Indicator (MRI):** 0.341 (Low Risk)
*   **RSI:** 52.83 (Neutral)
*   **PPO:** 0.5566
*   **Hybrid Signal:** cash_0%_Buy 90% of cash (5 shares - Safe - MRI:0.33)
*   **Recent (20-day) Relative Divergence Change:** +0.5 (Short-term increase)
*   **Expected Return:** -251.2% (Significant underperformance vs. S&P 500 over the long term)

**Analysis:**  The MRI indicates a low-risk environment. The RSI is neutral. The positive change in relative divergence suggests a recent improvement in performance compared to the benchmark, but the very negative expected return is a major concern. The recent price change of -2.47% reflects a negative short-term trend, but doesn't appear to be a drastic "issue" at this moment.

**4. Recent News & Significant Events**

*   **2025-07-15:** Major business developments, regulatory changes, or market events.
*   **2025-07-13:** Analyst discussions on recent performance and outlook.
*   **2025-07-16:** Stock volatility influenced by recent news, earnings reports, or executive actions.
*   **2025-07-12:** Experts highlighting risks and opportunities.

**Analysis:** The news suggests that TGTX is experiencing significant events that are impacting its stock price. Investors should carefully monitor company announcements and industry news.

**5. Recent Earnings Analysis**

| 날짜       | EPS   | 매출      |
| :--------- | :------ | :---------- |
| 2025-05-09 | 0.03  | 0.12 B$   |
| 2024-11-07 | 0.03  | 0.08 B$   |
| 2024-08-09 | 0.05  | 0.07 B$   |
| 2024-05-06 | -0.07 | 0.06 B$   |
| 2025-05-09 | -0.07 | 0.06 B$   |

**Analysis:** The earnings data shows a mixed performance. Recent EPS figures have been positive, but there have also been periods of negative EPS. Revenue has generally been increasing.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter    | Revenue | Profit Margin |
| :--------- | :-------- | :-------------- |
| 2025-03-31 | \$0.12B | 87.14%          |
| 2024-12-31 | \$0.11B | 85.77%          |
| 2024-09-30 | \$0.08B | 88.86%          |
| 2024-06-30 | \$0.07B | 88.70%          |
| 2024-03-31 | \$0.06B | 91.43%          |

**Capital and Profitability:**

| Quarter    | Equity  | ROE     |
| :--------- | :-------- | :-------- |
| 2025-03-31 | \$0.24B | 2.13%   |
| 2024-12-31 | \$0.22B | 10.49%  |
| 2024-09-30 | \$0.19B | 2.02%   |
| 2024-06-30 | \$0.18B | 3.87%   |
| 2024-03-31 | \$0.16B | -6.69%  |

**Analysis:** Revenue has been steadily increasing, and profit margins are very high. Equity is growing, but ROE (Return on Equity) is volatile, with a recent low.

**7. Overall Assessment**

TGTX presents a mixed investment picture.

*   **Positives:** Increasing revenue, high profit margins, low MRI, recent improvement in relative divergence, and potential short term upward trend.
*   **Negatives:** Underperformance compared to the S&P 500, volatile Alpha/Beta, negative expected return, recent stock price decrease, mixed earning data and recent significant events indicate risk.

**Conclusion:** The negative expected return is a major concern. Given the volatility and potential risks highlighted by recent news and the negative expected return, a cautious approach is warranted. Continuous monitoring of company announcements, financial results, and industry news is crucial for making informed investment decisions regarding TGTX.
